Skip to Content

Novo Nordisk A/S Class B NONOF

Morningstar Rating
$130.74 −3.52 (2.62%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NONOF is trading at a 496% premium.
Price
$134.19
Fair Value
$97.79
Uncertainty
Medium
1-Star Price
$549.46
5-Star Price
$79.45
Economic Moat
Vcyd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NONOF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$134.25
Day Range
$127.82135.75
52-Week Range
$75.50149.55
Bid/Ask
$125.87 / $135.60
Market Cap
$582.19 Bil
Volume/Avg
24,244 / 48,733

Key Statistics

Price/Earnings (Normalized)
46.35
Price/Sales
16.94
Dividend Yield (Trailing)
1.02%
Dividend Yield (Forward)
1.39%
Total Yield
1.66%

Company Profile

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
66,015

Competitors

Valuation

Metric
NONOF
LLY
SNY
Price/Earnings (Normalized)
46.3596.8410.57
Price/Book Value
41.8763.641.65
Price/Sales
16.9422.772.49
Price/Cash Flow
39.6794.6312.28
Price/Earnings
NONOF
LLY
SNY

Financial Strength

Metric
NONOF
LLY
SNY
Quick Ratio
0.490.680.83
Current Ratio
0.701.351.27
Interest Coverage
45.8214.1111.03
Quick Ratio
NONOF
LLY
SNY

Profitability

Metric
NONOF
LLY
SNY
Return on Assets (Normalized)
30.91%11.20%8.05%
Return on Equity (Normalized)
95.22%57.69%14.38%
Return on Invested Capital (Normalized)
73.76%20.65%10.85%
Return on Assets
NONOF
LLY
SNY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
YwbykfkzkLcq$598.1 Bil
Vertex Pharmaceuticals Inc
VRTX
CdrzmqjnSyrwgj$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
SpjlnxjjNqqdrqv$119.6 Bil
Moderna Inc
MRNA
LpyjgghqSqvss$47.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
SqmdcvhMkfsnkh$30.4 Bil
argenx SE ADR
ARGX
BlvrdqvdpCmmc$27.4 Bil
BioNTech SE ADR
BNTX
XlyhjdyfLdb$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
TydcyqxRccpncs$16.1 Bil
United Therapeutics Corp
UTHR
SpptyydCjv$14.7 Bil
Incyte Corp
INCY
CdnsxgnwCqnckr$12.9 Bil

Sponsor Center